Key Highlights

  • First patient dosed in the pivotal Phase 3 Beyond Harmony clinical trial of NTI164 in children with autism spectrum disorder on 21 September 2026
  • FDA cleared Neurotech's Investigational New Drug submission, authorising the company to commence a proposed US clinical development program
  • Notices of Allowance received from the USPTO for two US Patent applications covering key aspects of NTI164, titled "Compositions and Methods for Treating Neurological Disorders"
  • Company secured $3.15 million through an R&D tax incentive-backed Loan and binding commitments for approximately $4.5 million in Placement proceeds, with management stating it is fully funded through to top-line Phase 3 data

A Pivotal Milestone: First Patient Dosed in Beyond Harmony

Neurotech International Limited (ASX:NTI), a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, announced on 21 September 2026 that the first patient had been dosed in its Phase 3 Beyond Harmony clinical trial evaluating NTI164 in children with autism spectrum disorder (ASD). All six trial sites across Victoria, Queensland, New South Wales, Tasmania, and Western Australia have been initiated, and the study is designed to enrol up to 200 patients.

The commencement of dosing advances NTI164 into pivotal Phase 3 clinical development, which is the final and most significant trial stage before regulatory submission. The study is a national, multi-centre, randomised, double-blind, placebo-controlled design — the gold standard for pharmaceutical clinical evidence — evaluating efficacy, safety, and tolerability of NTI164. It will assess key behavioural and functional outcomes with a focus on core ASD symptoms while investigating neuroinflammatory pathways. Clinical endpoints have been aligned with relevant regulatory guidance.

Building on Phase II/III Harmony Data

Beyond Harmony builds on the clinical evidence generated in the 54-patient Phase II/III Harmony study, which reported clinically meaningful and statistically significant results across a range of validated measures, supported by a favourable safety profile. Those data formed part of the clinical evidence included in Neurotech's FDA-cleared Investigational New Drug (IND) submission. The trial also incorporates an adaptive design, allowing for pre-specified adjustments based on interim analyses while preserving scientific rigour and statistical integrity.

More than 300 enquiries from parents and caregivers were received following media coverage of the trial commencement, which the company said provides confidence in its ability to recruit participants within the planned timeframe.

FDA IND Clearance Opens US Pathway

The US Food and Drug Administration cleared Neurotech's IND submission for NTI164, formally authorising the company to commence its proposed US clinical development program. The submission included chemistry, Manufacturing and controls information, non-clinical data, and clinical information supporting the proposed program. A US study conducted under the cleared IND would comprise a population pharmacokinetic program designed to complement the Australian Phase 3 trial, generating pharmacokinetic data to support dose characterisation and future product registration.

Neurotech is also engaging with the Australian Therapeutic Goods Administration (TGA) to align its Australian and US regulatory strategies and explore the potential use of clinical data across multiple jurisdictions.

Patent Allowances Strengthen IP Position

During the quarter, Neurotech received Notices of Allowance from the USPTO for US patent applications No. 18/698,605 and No. 19/335,945, both titled "Compositions and Methods for Treating Neurological Disorders." The first application covers methods of reducing neuroinflammation using NTI164, while the second is directed to methods of treating specific neurological conditions. USPTO Notices of Allowance confirm the patent will be granted, strengthening the intellectual property foundation ahead of commercialisation.

Sector Context

Autism spectrum disorder affects an estimated 1 in 36 children in the United States according to CDC data, and no pharmacological treatment currently approved by the FDA specifically targets the core symptoms of ASD. NTI164 is a cannabidiol-based compound targeting neuroinflammatory pathways, a mechanism of action that has attracted substantial research interest. The absence of approved pharmacological treatments for core ASD symptoms represents a significant unmet medical need, and any compound demonstrating efficacy in a rigorous Phase 3 trial would enter a largely uncrowded therapeutic space with substantial global commercial potential.

Risks

Phase 3 Clinical Trials carry significant failure risk; the majority of drug candidates that enter pivotal trials do not achieve regulatory approval. The Beyond Harmony trial is designed for 200 patients, and any delays in recruitment, site initiation, or patient retention could extend the timeline to data readout. The Phase II/III Harmony study enrolled 54 patients, meaning the Phase 3 will need to confirm and extend findings across a substantially larger and potentially more heterogeneous population. Funding to the top-line data readout is stated as secured, but any trial design changes or cost overruns could alter that position. ASD trials face inherent measurement challenges given the variability of symptom expression across patients.

What to Watch Next

Enrolment progress in the Beyond Harmony trial is the primary operational focus for investors, given that patient recruitment pace determines the timeline to top-line data readout. Any updates on engagement with the TGA regarding the Australian regulatory pathway, or with potential strategic partners regarding commercialisation, would be significant developments. The formal issuance of the two US patents following the Notices of Allowance will strengthen the company's IP position for Partnership discussions.